In the company’s financial results for 2021 released on May 11, Takeda announced the decision to discontinue the development of TAK-609, a therapeutic for Hunter Syndrome. Additionally, Takeda is collaborating with JCR Pharmaceuticals in another therapeutic attempt for the condition.

Takeda Pharmaceutical announced positive results from the Phase III SHP643-301 trial of Takhzyro (lanadelumab) in kids ages 2 to <12 years with hereditary angioedema (HAE). The drug is already approved for HAE in people 12 years and older.

Patients infected with the Omicron variant of SARS-CoV-2 remain contagious for just as long as patients infected with earlier variants, according to a small study. Additionally, researchers said a drug used to treat a blood vessel condition called angioedema showed promise as a treatment for COVID-19 in lab experiments.

Takeda and Code Biotherapeutics announced a collaboration agreement to leverage the latter’s proprietary targeted 3DNA non-viral genetic medicine delivery platform for the design and development of gene therapies for rare diseases.

Seagen shared that the company’s Phase III trial of Adcetris (brentuximab vedotin) demonstrated significant improvements in the overall survival of patients diagnosed with advanced classical Hodgkin lymphoma.

With two assets licensed from Takeda, Oak Hill Bio launched with a focus on developing therapeutics for patients and extremely preterm infants who are suffering from rare autoimmune diseases.

The U.S. Food and Drug Administration approved Takeda Pharmaceutical Company Limited’s Vonvendi [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease (VWD) receiving on-demand therapy.

Takeda added some more firepower to the company’s immuno-oncology game on January 10 when the Japanese giant announced it will exercise an option to acquire U.K.-based Adaptate Biotherapeutics.

Shares of Takeda Pharmaceutical fell after the company announced the U.S. Food and Drug Administration rejected the New Drug Application for TAK-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis.

Four years after partnering with GammaDelta Therapeutics to develop therapies for solid tumors, Takeda Pharmaceutical pulled the trigger and exercised its option to acquire the London-based company.